These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 31119188)

  • 1. Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS.
    Akgün K; Kretschmann N; Haase R; Proschmann U; Kitzler HH; Reichmann H; Ziemssen T
    Neurol Neuroimmunol Neuroinflamm; 2019 May; 6(3):e555. PubMed ID: 31119188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosis.
    Hyun JW; Kim Y; Kim G; Kim SH; Kim HJ
    Mult Scler; 2020 May; 26(6):659-667. PubMed ID: 30912689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age-corrected neurofilament light chain ratio decreases but does not predict relapse in highly active multiple sclerosis patients initiating natalizumab treatment.
    Højsgaard Chow H; Petersen ER; Olsson A; Hejgaard Laursen J; Bredahl Hansen M; Oturai AB; Soelberg Sørensen P; Bach Søndergaard H; Sellebjerg F
    Mult Scler Relat Disord; 2024 Aug; 88():105701. PubMed ID: 38889559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of alemtuzumab over sNfL and sGFAP levels in multiple sclerosis.
    Sainz-Amo R; Rodero Romero A; Monreal E; Chico García JL; Fernández Velasco JI; Villarrubia N; Veiga González JL; Sainz de la Maza S; Rodríguez Jorge F; Masjuan J; Costa-Frossard L; Villar LM
    Front Immunol; 2024; 15():1454474. PubMed ID: 39224593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study.
    Uphaus T; Steffen F; Muthuraman M; Ripfel N; Fleischer V; Groppa S; Ruck T; Meuth SG; Pul R; Kleinschnitz C; Ellwardt E; Loos J; Engel S; Zipp F; Bittner S
    EBioMedicine; 2021 Oct; 72():103590. PubMed ID: 34571362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of elevated sNFL in a real-world setting: Results on 908 patients with different multiple sclerosis types and treatment conditions.
    Bava CI; Valentino P; Malucchi S; Bottero R; Martire S; Sapio AD; Bertolotto A
    Mult Scler Relat Disord; 2024 Aug; 88():105748. PubMed ID: 38959590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum neurofilament light chain is a useful biomarker in pediatric multiple sclerosis.
    Reinert MC; Benkert P; Wuerfel J; Michalak Z; Ruberte E; Barro C; Huppke P; Stark W; Kropshofer H; Tomic D; Leppert D; Kuhle J; Brück W; Gärtner J
    Neurol Neuroimmunol Neuroinflamm; 2020 Jul; 7(4):. PubMed ID: 32404429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis.
    Fox RJ; Cree BAC; de Sèze J; Gold R; Hartung HP; Jeffery D; Kappos L; Montalban X; Weinstock-Guttman B; Singh CM; Altincatal A; Belviso N; Avila RL; Ho PR; Su R; Engle R; Sangurdekar D; de Moor C; Fisher E; Kieseier BC; Rudick RA
    Neurology; 2024 May; 102(9):e209357. PubMed ID: 38648580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum neurofilament levels and patient-reported outcomes in multiple sclerosis.
    Galetta K; Deshpande C; Healy BC; Glanz B; Ziehn M; Saxena S; Paul A; Saleh F; Collins M; Gaitan-Walsh P; Castro-Mendoza P; Weiner HL; Chitnis T
    Ann Clin Transl Neurol; 2021 Mar; 8(3):631-638. PubMed ID: 33492760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measuring treatment response to advance precision medicine for multiple sclerosis.
    Calabresi PA; Kappos L; Giovannoni G; Plavina T; Koulinska I; Edwards MR; Kieseier B; de Moor C; Sotirchos ES; Fisher E; Rudick RA; Sandrock A
    Ann Clin Transl Neurol; 2021 Nov; 8(11):2166-2173. PubMed ID: 34704393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term prognostic value of longitudinal measurements of blood neurofilament levels.
    Häring DA; Kropshofer H; Kappos L; Cohen JA; Shah A; Meinert R; Leppert D; Tomic D; Kuhle J
    Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32817406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring.
    Calabresi PA; Arnold DL; Sangurdekar D; Singh CM; Altincatal A; de Moor C; Engle B; Goyal J; Deykin A; Szak S; Kieseier BC; Rudick RA; Plavina T
    Mult Scler; 2021 Sep; 27(10):1497-1505. PubMed ID: 33307998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study.
    Bittner S; Steffen F; Uphaus T; Muthuraman M; Fleischer V; Salmen A; Luessi F; Berthele A; Klotz L; Meuth SG; Bayas A; Paul F; Hartung HP; Linker R; Heesen C; Stangel M; Wildemann B; Then Bergh F; Tackenberg B; Kuempfel T; Weber F; Zettl UK; Ziemann U; Tumani H; Groppa S; Mühlau M; Lukas C; Hemmer B; Wiendl H; Gold R; Zipp F;
    EBioMedicine; 2020 Jun; 56():102807. PubMed ID: 32460167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis.
    Disanto G; Barro C; Benkert P; Naegelin Y; Schädelin S; Giardiello A; Zecca C; Blennow K; Zetterberg H; Leppert D; Kappos L; Gobbi C; Kuhle J;
    Ann Neurol; 2017 Jun; 81(6):857-870. PubMed ID: 28512753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Dietary Intervention on Serum Neurofilament Light Chain in Multiple Sclerosis.
    Bock M; Steffen F; Zipp F; Bittner S
    Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34764215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring of radiologic disease activity by serum neurofilaments in MS.
    Uher T; Schaedelin S; Srpova B; Barro C; Bergsland N; Dwyer M; Tyblova M; Vodehnalova K; Benkert P; Oechtering J; Leppert D; Naegelin Y; Krasensky J; Vaneckova M; Kubala Havrdova E; Kappos L; Zivadinov R; Horakova D; Kuhle J; Kalincik T
    Neurol Neuroimmunol Neuroinflamm; 2020 Jul; 7(4):. PubMed ID: 32273481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis.
    Siller N; Kuhle J; Muthuraman M; Barro C; Uphaus T; Groppa S; Kappos L; Zipp F; Bittner S
    Mult Scler; 2019 Apr; 25(5):678-686. PubMed ID: 29542376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MS.
    Kuhle J; Daizadeh N; Benkert P; Maceski A; Barro C; Michalak Z; Sormani MP; Godin J; Shankara S; Samad TA; Jacobs A; Chung L; Rӧsch N; Kaiser C; Mitchell CP; Leppert D; Havari E; Kappos L
    Mult Scler; 2022 Apr; 28(4):573-582. PubMed ID: 34378446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study.
    Frau J; Saccà F; Signori A; Baroncini D; Fenu G; Annovazzi P; Capobianco M; Signoriello E; Laroni A; La Gioia S; Sartori A; Maniscalco GT; Bonavita S; Clerico M; Russo CV; Gallo A; Lapucci C; Carotenuto A; Sormani MP; Cocco E;
    J Neurol; 2019 Oct; 266(10):2440-2446. PubMed ID: 31209573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered Cerebrospinal Fluid Neurofilament Light Chain but Not Neurogranin Levels Are Associated with Response to Ocrelizumab Treatment in Relapsing-Remitting Multiple Sclerosis: A Preliminary Study.
    Kızılay T; Akbayir E; Erol R; Demir AS; Özkan Yaşargün D; Yilmaz V; Tuzun E; Turkoglu R
    Eur Neurol; 2024; 87(4):203-210. PubMed ID: 38754397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.